cas 1171891-07-8, 5-Phenyl-3-pyridinyl boronic acid, pinacol ester

Articles about 1171891-07-8Total 3 be found

Enzyme-like Supramolecular Iridium Catalysis Enabling C?H Bond Borylation of Pyridines with meta-Selectivity
The use of secondary interactions between substrates and catalysts is a promising strategy to discover selective transition metal catalysts for atom-economy C?H bond functionalization. The most powerful catalysts are found via trial-and-error screening due to the low association constants between the substrate and the catalyst in which small stereo-electronic modifications within them can lead to very different reactivities. To circumvent these limitations and to increase the level of reactivity prediction in these important reactions, we report herein a supramolecular catalyst harnessing Zn???N interactions that binds to pyridine-like substrates as tight as it can be found in some enzymes. The distance and spatial geometry between the active site and the substrate binding site is ideal to target unprecedented meta-selective iridium-catalyzed C?H bond borylations with enzymatic Michaelis–Menten kinetics, besides unique substrate selectivity and dormant reactivity patterns.
Al-Shehimy, Shaymaa,Gramage-Doria, Rafael,Roisnel, Thierry,Trouvé, Jonathan,Zardi, Paolo
supporting information
p. 18006 - 18013
(2021/05/07)

An electroluminescent compound and an electroluminescent device comprising the same
The present invention relates to an organic light emitting compound represented by chemical formula 1 and an organic electroluminescent device including the same, and the organic light emitting compound according to the present invention has excellent luminous efficiency and material lifetime properties, and thus, the organic electroluminescent device having excellent luminous efficiency while having power efficiency and long durability can be manufactured. Chemical formula 1.
-
Paragraph 0227; 0302-0307; 0407; 0414-0419

(2021/01/30)

Pyrrolopyrimidines and Pyrrolopyridines
Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
-
Page/Page column 50-52

(2009/07/25)